MRTX News Alert Mirati Therapeutics Inc (MRTX) 19.41 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mirati Therapeutics Inc (MRTX) 19.41 $MRTX

Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients
PR Newswire - Tue Dec 23, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enroll patients with NSCLC and another will enroll patients with other solid tumors. Both cohorts will enroll only those patients that have specific MET driver mutations including MET gene point mutations, gene amplification, and MET or Axl gene rearrangements.
MRTX: 19.41 (+0.03)

Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
MRTX: 19.41 (+0.03)

Mirati beats 3Q profit forecasts
Automated Insights - Mon Nov 10, 7:31AM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a third-quarter loss of $8.6 million.
MRTX: 19.41 (+0.03)

Mirati Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:27AM CST

MRTX: 19.41 (+0.03)

Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 10, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2014 and provided an update on its drug development programs.
MRTX: 19.41 (+0.03)

Michael Grey Joins Mirati Therapeutics Board of Directors
PR Newswire - Thu Nov 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
MRTX: 19.41 (+0.03)

Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
PR Newswire - Wed Sep 10, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.
MRTX: 19.41 (+0.03)

Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
PR Newswire - Thu Sep 04, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression.
MRTX: 19.41 (+0.03)

Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
PR Newswire - Mon Aug 11, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations.
MRTX: 19.41 (+0.03)

Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Fri Aug 08, 7:00AM CDT
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided an update on its drug development programs.
MRTX: 19.41 (+0.03)

Mirati Therapeutics Added to Russell 2000 Index
PR Newswire - Mon Jun 30, 3:01PM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company has been added to the Russell 2000® Index following the annual reconstitution of its U.S. and global equity indexes on June 27, 2014.
MRTX: 19.41 (+0.03)

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome
PR Newswire - Tue Jun 17, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL) and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.
MRTX: 19.41 (+0.03)

Mirati Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
PR Newswire - Thu Jun 12, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 9:00 a.m. Eastern Time in New York.
MRTX: 19.41 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 78

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading

Top 5 Most Recently Viewed Articles

Lido Staked Ether Experiences Significant Price Fluctuations

Updated Category News Views 50

The Recent Surge in Lido Staked Ether Lido Staked Ether has recently recorded a notable price increase of 3.0% in just the last 24 hours, now trading at $2,344.75. This rise seems to go against its trend over the past week, during which time the asset experienced a slight decline of 1.0%, falling from $2,333.90. The cryptocurrency has impressive highs, having reached an...

Continue Reading
Stella Artois Showcases Friendship with Super Bowl Ad Featuring Icons

Updated Category News Views 665

Stella Artois Presents an Iconic Super Bowl LIX Ad This year, Stella Artois crafts a memorable advertisement for Super Bowl LIX, showcasing the significance of connection through everyday moments. The campaign, titled 'For Moments Worth More,' aims to highlight how the simple pleasures in life can be elevated with the right company and a refreshing Stella Artois lager....

Continue Reading
Glucotrack Appoints New VP to Bolster Regulatory Strategy

Updated Category News Views 229

Glucotrack Welcomes Ted Williams as VP of Regulatory Affairs Glucotrack, Inc. is proud to announce the addition of Ted Williams as the new Vice President of Regulatory Affairs. This strategic move marks a significant step for the company as it continues to innovate and develop solutions for individuals managing diabetes. With nearly 25 years in the industry, Williams...

Continue Reading
Landstar System's Special Dividend Announcement for Shareholders

Updated Category News Views 156

Landstar System, Inc. Declares Special Cash Dividend Recently, Landstar System, Inc. (NASDAQ: LSTR) made headlines with an exciting announcement: a special one-time cash dividend of $2.00 per share. This decision, declared by the Board of Directors on a recent date, reflects the company's robust financial health and commitment to returning value to its shareholders....

Continue Reading
Market Insights: Economic Indicators and Trends to Watch

Updated Category News Views 276

Key Economic Indicators to Watch As we navigate through the current trading landscape, several economic indicators and events are set to shape the market narrative. Understanding these factors is crucial for informed trading decisions. Upcoming Economic Releases Starting the week, we have some pivotal economic releases lined up: Monday's Highlights The week begins with...

Continue Reading